Phaseline

Companies › Cellcolabs Clinical

Cellcolabs Clinical: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Cardiovascular, Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
StromaForte
Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
–Phase 1Musculoskeletal Injury; Cardiovascular DiseasesOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06074783StromaFortePhase 1Musculoskeletal InjuryOtherOct 2027
NCT06087848StromaFortePhase 1Cardiovascular DiseasesCardiovascularOct 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.